Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGARO UC 301 induction study of SHP647 in moderate to severe ulcerative colitis
MOH_2018-01-17_002020Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ontamalimab in autoimmune colitis (3 arms), sponsored by Takeda. Primary endpoint: Induction of remission. Started Dec 2017; status: active, not recruiting.
02
Drugs
ontamalimab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2018-01-17_002020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-01-17_002020.